Relief Therapeutics Holding AG (RLFTF)

[Uncle Gee Gee]

Updated Summary of known facts about RLFTF: Aviptadil RLF-100 VIP
(updated 9/6/20)

Several individuals have requested that I provide an update to my original summary about RLFTF. This post highlights several key updates since then.


Original Post on August 23, 2020

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157819838
New Note: Aviptadil is a safe, synthetic version of a naturally occurring peptide in the human body, which increases surfactant production in the lungs.


Update August 28, 2020

On August 28, an official pre-print that “describes the first 6 patients with Acute Respiratory Failure” was released, providing new details about their incredible results:

• Before aviptadil, each of the patients were "showing active signs of clinical deterioration... despite receiving maximal intensive care for COVID-19 related respiratory failure”.
• The document states that after taking aviptadil, all 6 patients survived, all showed x-ray improvements within the first 72 hours, and all showed improvement in blood oxygenation.
• “The short term survival of 6/6 patients with respiratory failure in the setting of COVID-19 and major comorbidity is the most dramatic response ever seen with an antiviral agent.”

https://www.preprints.org/manuscript/202008.0640/v1

Update August 31, 2020

Relief up-listed from the OTC Pink exchange to the OTCQB exchange, which is “recognized by the Securities and Exchange Commission as an established public market” that is “designed for early-stage and developing companies”. “This will allow a broader range of investors to invest in Relief Stock.”

https://relieftherapeutics.com/relief-announces-successful-up-listing-from-otc-pink-to-otcqb-and-capital-increase-from-its-share-subscription-facility-with-gem/

Update September 2, 2020

On September 2nd, a fourth FDA clinical trial #NCT04536350 was initiated for an inhaled version of aviptadil as a preventative treatment. The trial will take place in Switzerland, and is expected to finish in December of 2021.

The trial document that was submitted made a case for aviptadil’s safety, as well as its long-term role for ARDS and other medical conditions:

The Covid front-runner remdesivir “is the first and so far, only approved treatment for COVID-19”, but unfortunately, it “did not find significant improvement in COVID- 19 patients”. Also, other antiviral drugs “have not found a significant benefit”, and thus “there is still a desperate need for an effective, safe treatment for COVID-19”.

Aviptadil has been approved safe in Europe for sarcoidosis, pulmonary fibrosis, bronchospasm, erectile dysfunction, and ARDS. ARDS in particular “is a known lethal complication” that “may result in organ failure”. In the early 2000’s, seven out of “eight patients with severe ARDS on mechanical ventilation” were “successfully extubated”.

Aviptadil was also given to animals with lung injury, and showed to “restore barrier function” and to “protect the lung and other organs from failure”.

Additionally, “healthy volunteers have shown that inhaled aviptadil is well tolerated with few adverse effects.”

Update September 4, 2020

On September 4th, Relief announced they have hired Dr. Corte as the new CMO (Chief Medical Officer) to head up the clinical development of aviptadil in Europe, which confirms Relief’s commitment to additional international expansion.

Relief’s Chairman said that Dr. Corte “will be a great asset to Relief as aviptadil advances in clinical development in Europe and the U.S. and as we hopefully prepare submissions for marketing approval soon."

In this article, we also received further confirmation that “aviptadil has broad potential to help patients with other acute and chronic lung diseases, as well as earlier-stage COVID-19 patients”.

https://relieftherapeutics.com/relief-appoints-gilles-della-corte-m-d-as-chief-medical-officer/